PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
PTC Therapeutics (NASDAQ:PTCT) VP Sells $12,337.92 in Stock
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Boulding sold 192 shares of the stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $64.26, for a total transaction of $12,337.92. Following the sale, the vice president directly owned 105,272 shares of the company’s […]
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Boulding sold 192 shares of the company's stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $64.26, for a total value of $12,337.92. Following the sale, the vice president owned 105,272 shares in the company, valued at approximately $6,764,778.72. This trade represents a 0.18% decrease in their ownership of the stock. The sale wa…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
